Navigation Links
CVBT Shareholders Vote for Change

LAS VEGAS, June 9, 2013 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (CVBT) announced today that its shareholders have voted by over 60% to amend the bylaws of CVBT, remove specific directors of the Company and authorize the remaining directors to consider a financing proposal. 

The board members who have been removed effective June 7, 2013 are Daniel C. Montano, John (Jack) Jacobs, Ernest C. Montano, Viktoriya T. Montano, Ernest Montano III, and Joong Ki Baik.

The remaining two directors, Mickael A. Flaa and Grant Gordon, have appointed three new directors to the CVBT Interim Board of Directors: Calvin A. Wallen III, Jon Ross, and Robert Schleizer. The new directors bring financial, legal, securities and turnaround experience to CVBT's Board.

The Interim Board has met and ratified the bylaw amendments approved by the shareholders, authorized management to consider the financing proposal, terminated prior management and appointed Calvin A. Wallen III as Chairman of the Board, and Mickael A. Flaa as President and CFO.

More information on the new directors will be posted to CVBT's website in the very near future. 

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company is the sponsor of a Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Late-Stage trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contacts:
Allison Caplan
CardioVascular BioTherapeutics, Inc.
(702) 839-7200

CVBT Mailing List
To be added to the CVBT Mailing List, please send your contact information to

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Invites to the Annual Shareholders Meeting 2013
2. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
3. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
4. 3SBio Inc. Announces Shareholders Approval of the Amended Merger Agreement
5. Medifirst Solutions, Inc. Announces Update To Shareholders
6. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
7. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
8. Update to Shareholders on Dividend Payment: Medisafe 1 Technologies Corporation Files Corporate Action Form with FINRA for the Dividend Distribution to its Shareholders
9. 3SBio Inc. Announces Receipt of Amended "Going Private" Proposal at $16.70 Per ADS and Intent to Adjourn Extraordinary General Meeting of Shareholders
10. Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
11. 3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... -- Booth #3506 – Claymount is featuring its full line of ... Radiological Society of North America (RSNA) ... the Netherlands , Claymount is part of ... VAR ) and is one of the world,s leading suppliers ... exposure control systems for controlling dose during medical X-ray imaging. ...
(Date:12/1/2015)... WASHINGTON and TELTOW, Germany ... SensoMotoric Instruments (SMI) , a leading global manufacturer of ... RightEye LLC has included SMI remote eye trackers ... that help healthcare providers assess concussions, eye sight, and ... SMI RED -oem technology is part of SMI,s mass-market-ready ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Rehabilitation P.C.went to NASDAQ to educate the personnel on spinal decompression therapy and ... the spine, a nonsurgical procedure. The benefits come from creating negative intradiscal pressure ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... detailing the important role that meat and poultry play in a healthy, ... poultry, a nutrition quiz where visitors can check their “meat IQ,” a section ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... World ... the Multi Jar, a container patent that allows for easier packing and organizing of ... US is worth $90 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:12/1/2015)... ... 01, 2015 , ... Henderson, a town of about 6,300 ... through a partnership this year with Aeneas Internet and Telephone. , With faster ... for entrepreneurs who want to build a business. Whether startups or long established ...
Breaking Medicine News(10 mins):